MedTrace Logo

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

NCT05304949 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2025-07-04

No results posted yet for this study

Summary

This study was an open-labeled, multicenter, single arm, observational post-marketing surveillance study under routine clinical practice with no mandated treatments, visits or assessments.

Conditions

  • Retinopathy of Prematurity

Interventions

OTHER

Lucentis

There was no treatment allocation. Patients administered Lucentis by prescription were enrolled.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
0 Years
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2025-01-11
Completion
2025-01-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304949 on ClinicalTrials.gov